Thromboxane A2 and Osteoarthritis
Official title: Throboxane Effect on Chondrocytes; Role in Osteoarthritis
Run by Centre Hospitalier Universitaire de Nice · NCT05593640 · Data updated 2026-11-12
Researchers are testing whether thromboxane A2 affects cartilage cells and osteoarthritis in humans and animals to see if it could help explain cartilage health and point toward new therapies.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 1 site (Nice) |
| Status | Recruiting |
| Started | September 1, 2022 |
| Main results expected | September 1, 2023 |
| Study ends | June 25, 2027 |
| Registry record updated | June 29, 2026 |
| Trial ID | NCT05593640 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with knee osteoarthritis and effusion who are not on anticoagulants and do not have other inflammatory diseases.
✕Probably not a fit
Patients without knee OA or with inflammatory diseases or on anticoagulants may not benefit from this research.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates how thromboxane A2 (TXA2) influences chondrocyte differentiation and cartilage homeostasis. It includes in vitro experiments, a rat OA model to relate TXA2 levels with disease progression, and a small human cohort to examine associations between TXA2 in blood and synovial fluid with OA features. The study compares TXA2 effects to prostacyclin, another arachidonic acid metabolite, on thermogenic markers and cartilage biology. Results could inform nutritional or pharmacological approaches to OA and related metabolic conditions. The research is led by CHU de Nice with collaboration from the French Society of Rheumatology.
Why it matters
Potential benefit: If TXA2 pathways are linked to cartilage health, insights could lead to new strategies to slow OA progression or alleviate symptoms.
How similar studies have gone: Previous work has explored lipid metabolites in joint biology, but this specific TXA2–chondrocyte link in OA is exploratory and not yet established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * presence of knee osteoarthritis with effusion, , no inflammatory disease Exclusion Criteria: * anticoagulant treatment * inflammatory disease
Where it's running
-
CHU de NICE
Nice, France Recruiting
Study contacts
- Study coordinator: Christian ROUX, MD, PhD
- Email: roux.c2@chu-nice.fr
- Phone: +33492035491
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Autologous adipose-derived stem cell injections for knee osteoarthritis
We’re testing whether injecting a patient’s own fat-derived stem cells into the knee can help people with knee OA feel less pain and move better, compared with a standard hyaluronic acid treatment.
-
Early wear of a Vitamin E-infused liner in a dual-mobility hip replacement
This study tests whether a Vitamin E-infused liner in a dual-mobility hip implant wears as little as a conventional liner over two years in adults needing hip replacement.
-
Preoperative Music to Ease Anxiety Before Hip or Knee Replacement
Patients awaiting hip or knee replacement listen to their own music through noise‑canceling headphones to see if it lowers preoperative anxiety.
-
Weight-bearing dangling exercises vs VMOb NMES for knee osteoarthritis
This study tests whether weighted dangling exercises or VMOb muscle NMES help people with knee osteoarthritis.
-
Post-op prednisone vs standard steroid regimen after knee or hip replacement
This study tests a 5-day oral prednisone course after knee or hip replacement to see if pain, swelling, and glucose control are better or different than the usual intraoperative steroid approach.
-
AI-based prediction of five major diseases using integrated health data
Researchers are testing an AI model to see if they can predict the onset of five major diseases in adults 30–65 by combining medical records with biospecimens and lifestyle data.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.